Experimental drugs from Roche and Eli Lilly both failed to halt Alzheimer's disease in a phase 2/3 trial spearheaded by Washington University in St. Louis.
The trial evaluated Roche's gantenerumab and Eli Lilly's solanezumab in a study focused on rare autosomal dominant Alzheimer's disease, which is caused by gene mutations that follow generations. The trial, which started in 2012, included 194 participants who were given solanezumab, gantenerumab or a placebo.
Roche said it will conduct separate studies of gantenerumab against a form of Alzheimer's disease not directly caused by gene mutations and will have results by 2022.
Lilly said it won’t pursue an application for regulatory approval of solanezumab to treat dominantly inherited Alzheimer’s but will continue to test the experimental drug in other clinical trials.
Read the Roche press release
Read the Eli Lilly press release
